| scholarly article | Q13442814 |
| P2093 | author name string | Schröder FH | |
| Kranse R | |||
| van der Maas P | |||
| Beemsterboer P | |||
| Hoedemaeker R | |||
| Kruger AB | |||
| Rietbergen J | |||
| P2860 | cites work | Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements | Q34425649 |
| Histologic grading of prostate cancer: a perspective | Q35959663 | ||
| Case-control study of screening for prostatic cancer by digital rectal examinations | Q39243454 | ||
| The American cancer society national prostate cancer detection project. Findings on the detection of early prostate cancer in 2425 men | Q39244114 | ||
| Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. | Q39377886 | ||
| Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies | Q39378933 | ||
| Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council | Q39424081 | ||
| Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer | Q39445032 | ||
| Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer | Q39458834 | ||
| Ethics of a prostate cancer screening trial. | Q40388034 | ||
| The palpable nodule of prostatic cancer. Results 15 years after radical excision | Q43780142 | ||
| Prediction of the effects and costs of breast-cancer screening in Germany | Q44808997 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1817-1823 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer | |
| P478 | volume | 90 |
| Q39590814 | A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate. |
| Q39772569 | A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan |
| Q33396700 | An image analysis method for prostate tissue classification: preliminary validation with resonance sensor data |
| Q78944899 | Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease |
| Q39796282 | Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy |
| Q36946259 | Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. |
| Q33744340 | Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians |
| Q53806279 | Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. |
| Q33841144 | Cancer screening in the elderly population |
| Q38965360 | Clarifying the PSA grey zone: The management of patients with a borderline PSA. |
| Q36861719 | Controversies regarding screening for prostate cancer |
| Q34294898 | Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
| Q36039229 | Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility |
| Q38109810 | Defining the threshold for significant versus insignificant prostate cancer. |
| Q93271346 | Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men |
| Q39767324 | Detection of clinical unilateral T3a prostate cancer - by digital rectal examination or transrectal ultrasonography? |
| Q34233827 | Detection of prostate cancer by prostate-specific antigen |
| Q39744709 | Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. |
| Q59187198 | Diagnostic Value of Finger-guided Prostate Nodule Biopsy Combined With Systemic Random Biopsy |
| Q52659314 | Dielectrophoresis-based microfluidic platforms for cancer diagnostics. |
| Q39317766 | Dielectrophoretic separation of prostate cancer cells |
| Q39786539 | Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer |
| Q34555221 | Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study |
| Q39718275 | Digital rectal examination is barrier to population-based prostate cancer screening |
| Q37008617 | Digital rectal examination: national survey of undergraduate medical training in Ireland |
| Q37378442 | Do patients undergo prostate examination while having a colonoscopy? |
| Q40046120 | Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death |
| Q35145693 | Early diagnosis and surgical management of prostate cancer |
| Q39579014 | Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening |
| Q39605971 | Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination |
| Q47254420 | Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis |
| Q41832537 | External validation of an artificial neural network and two nomograms for prostate cancer detection |
| Q42914714 | False-positive screening results in the Finnish prostate cancer screening trial |
| Q39677104 | Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). |
| Q73952737 | Identification of genetic markers for prostatic cancer progression |
| Q33891781 | Imaging and intervention in prostate cancer: Current perspectives and future trends |
| Q35123260 | Imaging clinically localized prostate cancer |
| Q63966369 | Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years |
| Q36743703 | Influence of Long-Distance Bicycle Riding on Serum/Urinary Biomarkers of Prostate Cancer. |
| Q55282801 | Innovative Diagnostic Methods for Early Prostate Cancer Detection through Urine Analysis: A Review. |
| Q39713997 | Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer? |
| Q34555011 | Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). |
| Q39708636 | Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature |
| Q35775441 | Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate-specific antigen? |
| Q39589717 | Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial |
| Q48588663 | Lest we abandon digital rectal examination as a screening test for prostate cancer |
| Q35068260 | MRI-targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men. |
| Q38322905 | Magnetic resonance imaging-guided prostate biopsy: present and future |
| Q36925172 | Management of the asymptomatic BRCA mutation carrier |
| Q40302020 | Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters |
| Q42129299 | Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features |
| Q37175042 | Multi-marker testing for cancer: what can we learn from modern prenatal testing for Trisomy-21. |
| Q38125636 | Multidimensional MR spectroscopic imaging of prostate cancer in vivo |
| Q35555399 | Novel prostate cancer biomarkers derived from autoantibody signatures |
| Q92640606 | Nuclear magnetic resonance spectroscopy of human body fluids and in vivo magnetic resonance spectroscopy: Potential role in the diagnosis and management of prostate cancer |
| Q36598343 | Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. |
| Q64264017 | Photoacoustic tomography for imaging the prostate: a transurethral illumination probe design and application |
| Q33778985 | Predictive value of digital rectal examination for prostate cancer detection is modified by obesity |
| Q36018610 | Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? |
| Q44279536 | Preventive health care for older patients |
| Q79341930 | Prostate cancer detection with an improved resonance sensor system: parameter evaluation in a silicone model and on human prostate tissue in vitro |
| Q39707623 | Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice |
| Q80297986 | Prostate cancer pathology, screening, and epidemiology |
| Q42848548 | Prostate cancer screening: Canadian guidelines 2011 |
| Q35720552 | Prostate-specific antigen and screening for prostate cancer |
| Q53565180 | Prostate-specific antigen cut-off point of 2.5 ng/mL and increasing the number of prostate biopsies results in the detection of curable prostate cancer even in Japanese population. |
| Q35840271 | Prostate-specific antigen in the early detection of prostate cancer |
| Q33989110 | Prostate-specific antigen levels in the United States: implications of various definitions for abnormal |
| Q39556871 | Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination |
| Q38408501 | Prostate-specific antigen-based prostate cancer screening: Past and future |
| Q51019666 | Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee. |
| Q48575752 | Re: Lest we abandon digital rectal examination as a screening test for prostate cancer |
| Q74128561 | Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention |
| Q38068114 | Risk stratification in prostate cancer screening. |
| Q37970913 | Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination |
| Q73365035 | Screening for prostate cancer |
| Q24201690 | Screening for prostate cancer |
| Q24245476 | Screening for prostate cancer |
| Q45072760 | Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). |
| Q33786256 | Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness |
| Q37803538 | Screening for prostate cancer: a controversy or fact |
| Q35158137 | Screening for prostate cancer: are digital rectal examinations being performed? |
| Q36152421 | Screening for prostate cancer: early detection or overdetection? |
| Q74116564 | Screening for prostatic cancer and its evolution within Britain |
| Q73280460 | Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial |
| Q39595302 | Serendipity in detecting disease in low prostate-specific antigen ranges. |
| Q39781202 | Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial |
| Q34216127 | State-of-the-art staging in prostate cancer |
| Q59310044 | Study of the Aggregation of DNA-Capped Gold Nanoparticles: A Smart and Flexible Aptasensor for Spermine Sensing |
| Q35663895 | Studying the distribution of deep Raman spectroscopy signals using liquid tissue phantoms with varying optical properties |
| Q40469023 | The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. |
| Q37777325 | The implementation of screening for prostate cancer |
| Q74373920 | The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer |
| Q36238011 | The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study |
| Q26849794 | The role of magnetic resonance imaging in the diagnosis and management of prostate cancer |
| Q35675436 | The story of the European Randomized Study of Screening for Prostate Cancer |
| Q33385858 | The trends in prostate specific antigen usage amongst United Kingdom urologists--a questionnaire based study |
| Q34394012 | The value of current diagnostic tests in prostate cancer screening |
| Q33971026 | The value of prostate-specific antigen in Asia |
| Q90688552 | Translation and cultural adaptation of a prostate cancer screening decision aid: a qualitative study in Portugal |
| Q39770209 | Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam |
| Q36123823 | Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers |
| Q36682283 | What should a urologist know about hereditary predisposition to prostate cancer? |
| Q40032193 | Why I cannot find the prostate? Behind the subjectivity of rectal exam. |
| Q73253937 | [Attitude of primary care physicians to early detection of prostatic cancer through prostate-specific antigen] |
| Q84203558 | [How to select the best candidates for prostate biopsies? The role of traditional tools and contribution of new biomarkers in prostate cancer] |
| Q52915870 | [The significance of rebiopsy in the diagnosis of prostate cancer]. |
| Q79077771 | [Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications] |
| Q24669748 | alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation |
Search more.